Sciformix Announces Expansion into Europe with New Office in UK
Sciformix Corporation has opened a new office in Manchester, UK expanding its global presence and footprint to include the European region. For more than 7 years, Sciformix has been supporting life science organizations with high quality services in the areas of safety and risk management, regulatory affairs and operations and clinical research and post-approval support. The opening of the new European office demonstrates Sciformix’s scalability and preparedness to combine optimized on-shore/off-shore models that enhance client value and experience while maximizing cost benefits.
By opening an office in the UK, Sciformix will seek to better service its existing global and European clients with near-shore presence and also build new relationships with potential clients across EMEA to further grow and diversify its client and revenue base. Sciformix’s unique combination of expert talent, LEAN processes, technology innovation and flexible operations provides an attractive option to life science organizations, small and large, who are seeking to establish strategic outsourcing partnerships.
With this expansion into Europe to complement its already established presence in the US and Asia with over 750 employees, Sciformix will be within arms reach of clients’ operations across three continents. With delivery functions operating also out of the European Union (EU), clients will experience Sciformix even more as an extension of their own operations.
For years, industry groups have lobbied the UK government to help establish and nurture a life sciences hub, similar to that in Boston, US where world-class research institutions abut promising biotech start-ups and Big Pharma. The UK is now striving to brand itself as a hotbed for biotech R&D, promising new funds for start-ups, pledging to speed up its approval process and courting some major players to deepen their roots in the country. Sciformix will be able to take advantage of this and play a key role in this growth.
Manish Soman, President & CEO, Sciformix Corporation commented: “Sciformix’s long-term strategy focuses on evolving and enhancing our service and technology offerings, broadening our global reach and growing and diversifying the client and revenue base. Building a European hub will support all of these objectives. With our clients’ growth in emerging markets, it has become increasingly important for us to truly understand the local safety and regulatory challenges our clients face and to become the partner of choice when it comes to outsourcing these activities. Sciformix is such a trusted provider.”
The new office will support all service lines, however, the initial focus will be on Consulting, Safety and Risk Management, Regulatory, and Labelling services.
Related News
-
News US BIOSECURE Act passed by US House of Representatives
The controversial act, which has already impacted several foreign companies operating in the US, was passed by the House of Representatives on September 9, 2024. It is now headed for the US Senate before it can be signed into law by President Joe Biden... -
News Pharma Supply Chain People Moves
The latest appointments, promotions, and structural changes across the pharmaceutical supply chain. -
News Drug prices agreed upon as part of the US Inflation Reduction Act
The Inflation Reduction Act brought into constitution by the Biden administation in 2022, which proposed a drug price negotiation between the government and pharmaceutical companies, has reached it's first agreement. -
News BIOSECURE Act continues to loom over Chinese pharma manufacturers
With the US BIOSECURE Act on its way to passing into legislation, Chinese companies are facing declining revenues within the first half of 2024 as US pharmaceutical and healthcare companies pull their businesses from the country. -
News Ophthalmologic drug product Eylea faces biosimilar threats after FDA approvals
Regeneron Pharmaceutical’s blockbuster ophthalmology drug Eylea is facing biosimilar competition as the US FDA approves Biocon’s Yesafili and Samsung Bioepis/Biogen’s Opuviz. -
News ONO Pharmaceutical expands oncology portfolio with acquisition of Deciphera
ONO Pharmaceutical, out of Japan, is in the process of acquiring cancer-therapy maker Deciphera Pharmaceuticals for US$2.4 billion. -
News First offers for pharma from Medicare drug price negotiations
Ten high-cost drugs from various pharma manufacturers are in pricing negotiations in a first-ever for the US Medicare program. President Biden’s administration stated they have responded to the first round of offers. -
News Eli Lilly’s Zepbound makes leaps and bounds in weight-loss drug market
In the last week, Eli Lilly has announced their partnership with Amazon.com’s pharmacy unit to deliver prescriptions of Zepbound. Zepbound has also surpassed Novo Nordisk’s Wegovy for the number of prescriptions for the week of March 8.&nbs...
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance